Although cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer, the global consensus is that primary human papillomavirus (HPV) testing for cervical screening increases detection of highgrade cervical intraepithelial neoplasia (CIN) and invasive cancer. However, the optimal triage strategy for HPV-positive women to avoid over-referral to colposcopy may be setting specific. As Japan requires data that have been generated domestically to modify screening guidelines, we conducted a 3-year prospective study, COMparison of HPV genotyping And Cytology Triage (COM-PACT), to evaluate the potential role of HPV16/18 partial genotyping and cytology for primary HPV screening. In total, 14 642 women aged 20 to 69 years undergoing routine screening at 3 centers in Hokkaido were enrolled.
Conventional cytology and HPV testing were carried out. Women with abnormal cytology or HPV16/18 positivity underwent colposcopy. Those with 12 other high-risk (hr) HPV types underwent repeat cytology after 6 months. Primary study endpoints were detection of high-grade cervical disease defined as CIN2/ CIN3 or greater as determined by consensus pathology. Prevalence of cytological abnormalities was 2.4%. hrHPV, HPV 16, and HPV 18 were detected in 4.6%, 0.9%, and 0.3% of women, respectively. HPV16/18 were detected in all (8/8) invasive cervical cancers and in all (2/2) adenocarcinomas in situ. Both cytological abnormalities and hrHPV positivity declined with increasing age. This is the first Japanese study to investigate the role of partial genotyping and cytology in an HPV-based screening program. Results should help policy-makers develop guidelines for future cervical screening programs and management of cervical abnormalities based on HPV genotype.
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| INTRODUCTION
Over the past 50 years, cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer. 1 However, even in countries with organized screening programs, cervical cancer remains a significant cause of morbidity and mortality.
One important limitation of cytology is the low sensitivity of a single screen. Consequently, women must attend for repeated screens to achieve acceptable sensitivity. Furthermore, in vaccinated cohorts, the prevalence of cervical abnormalities will decrease, lowering the PPV of cytology-based testing which will, in turn, affect cytotechnician training and quality assurance in a vaccinated population. 2, 3 Almost all high-grade CIN grades 2 and 3, AIS and ICC are caused by persistent infection with 1 of 14 hrHPV. 4 Increased understanding of the natural history of cervical cancer, and the essential role of HPV, has prompted many countries to move towards a screening program which uses molecular testing for hrHPV alone as the primary screening test or, less common, an HPV test combined with cytology (co-testing). The Netherlands, for example, began 5-yearly primary hrHPV screening in January 2017, Australia will follow in December 2017, and the UK and New Zealand from 2018. [5] [6] [7] Pooled data from 4 European RCT of primary HPV screening showed that, overall, women who were randomized to HPV screening were at a significantly decreased risk of ICC than women in the cytology control arms. 8 However, compared to cytology, concerns have been expressed about the lower specificity of hrHPV testing as a primary screening tool, which may result in increased colposcopy referrals and overdiagnosis and/or overtreatment of regressive CIN2 lesions in women <30 years. 9 It is, however, also known that in hrHPV-positive women, the risk for CIN2 + lesions and ICC is not the same for all HPV types. One US study showed that women positive for HPV 16 were at the highest risk for CIN3 + in both the short and longer term and the risk was also higher for HPV 18, albeit not as high as HPV 16. 10 Similar results were also found in a Japanese longitudinal study. 14 Biennial screening using cytology began in the 1960s. Although it is still used as the primary screening method, HPV testing to triage ASC-US was introduced in 2011. 15 Despite this, LBC use is not widespread and women must often be recalled to give another sample if they had an abnormal Pap smear. This, combined with the fact that there is no national call-recall system, results in many women at higher risk for cervical cancer or cervical precancers being lost to follow up. Given this situation, it is essential that when women do attend for screening, they undergo as accurate a screening test as possible so that those most at risk can be identified, triaged, and followed up as appropriate.
As the Japanese MHLW requires data that have been generated within Japan to modify national screening guidelines, we conducted a 3-year prospective study, COMPACT, to evaluate the potential role of HPV16/18 partial genotyping and cytology for primary HPV cervical cancer screening. Here we present the study protocol and baseline characteristics of the study population, including hrHPV prevalence, cytology results and cervical disease status by age and HPV status. which has a population of 341 000 and is the second largest city in Hokkaido; and Kushiro (center 3), a port city with a population of 173 000 and the largest city in more rural Eastern Hokkaido.
| MATERIALS AND METHODS

| Study design
Apart from age, inclusion criteria were as follows: informed con- Because this was a study that took place within regular communitybased screening, available demographics on the participants were limited. Information used for screening such as age, menopausal status, previous history of cervical disease and HPV vaccination status was obtained. Smoking history could only be ascertained for those participants also undergoing lung cancer screening and was not reliable, as younger women were less likely to be included. Furthermore, these data were available from only 1 of the 3 screening centers. Consequently, smoking status is not reported in the present study. Therefore, after obtaining written informed consent, a speculum examination was carried out and 2 cervical samples were collected using a cervical brush according to the manufacturer's instructions; 1 for conventional cytology and the other for hrHPV testing. Women with NILM cervical cytology and a negative hrHPV result (group 1) were assigned to routine screening in 2 years. Those who had NILM cervical cytology, but were positive for 1 or more of the other pooled hrHPV types (group 2) underwent repeat cytology after 6 months. Of these women, those who were cytology positive after 6 months were assigned to either group 5 or group 6 depending on the cytology results. institution is shown in Table 3 . As with abnormal cytology, the prevalence of hrHPV infection also decreased significantly with increasing age. At enrolment, hrHPV was detected in 16.2% of women 20-29 years of age, but by age 40-49 years, the prevalence of hrHPV had decreased to only 5.2%, and for women aged 60-69 years it was 2.7% (P for trend = .003). Similar reductions in prevalence with increasing age were also observed for both HPV 16 and HPV 18. For HPV 16, prevalence was 4.6%, 0.9% and 0.5% (P for trend = .003) for women aged 20-29 years, 40-49 years and 60-69 years, respectively; for HPV 18, it was 1.4%, 0.3% and 0.1% (P for trend <.001), respectively.
| Confirmed cervical disease at baseline
Of the 480 women referred for colposcopy at baseline, 346 (72.1%) underwent colposcopy and 55 (11.5%) underwent repeat cytology. Given this situation, when women do attend for screening, it is essential that they undergo as accurate a screening test as possible so that those most at risk can be identified, triaged and followed up as appropriate. To try and identify the best strategy to achieve this, combined with the fact that the MHLW requires data that have been generated within Japan to modify national screening guidelines, we carried out a 3-year prospective study, COMPACT, to compare HPV16/18 partial genotyping and cytology for primary HPV cervical cancer screening. Here we present the baseline characteristics of the study population.
Mean age of women in the present study is considerably higher than in the ATHENA study 12 (50.6 AE 11.1 years vs 39.8 AE 12.3 years); however, it is only slightly higher than an ongoing Japanese population-based screening trial, CITRUS, which is comparing cytology alone with HPV and cytology co-testing. 16 The latter used both a hospital-based and local government-run screening program and the mean age was 44.3 AE 3.7 years. This higher mean age is representative of women undergoing cervical screening in Japan as there is no cut-off age for cervical screening. Furthermore, women who attend local government screening programs tend to be those who do not qualify for workplace screening programs and therefore may either be retired or women who have gone back to work part-time once their children reach a certain age.
The overall rate of cytological abnormalities (ASC-US or worse) was 2.4%; of these, 1.1% was ASC-US. These results are similar to the CITRUS study where 2.2% were ASC-US or more and, of these, 1.3% were ASC-US. 16 Our results are also comparable with cytology results for the Japanese local government population-based screening programs reported by the Regional Public Health Services and Health Promotion Services. 17 As a result of the older mean age of participants, the overall prevalence of hrHPV was also considerably lower (4.8%) in the present study compared to the ATHENA study (12.6%) and in CITRUS (11.7%). However, it is similar to a further 2 Japanese studies on co- (Qiagen, Germantown, MD, USA), which does not allow for partial genotyping, and comparing cytology to HPV co-testing, is also about to start. 23 However, the global consensus is that there is strong and uniform evidence for the efficacy of HPV-based screening, as it allows earlier detection of cervical precancers and is more effective than cytology-based screening because it permits an extension of screening intervals at equal or better safety while reducing harm from too frequent screening. 24, 25 Most national and international organizations also agree there is little evidence for the usefulness of adding cytology to primary HPV screening in the form of co-testing.
This was reinforced recently by a draft from the US Preventative
Task Force (USPTF) also withdrawing its recommendations for HPV and cytology co-testing. 26 What has not been agreed on is, to a lesser extent, screening interval, and the optimal triage strategy for HPV-positive women, a critical component of an HPV-based screening program to avoid referring all HPV-positive women to colposcopy. Several potential options include: cytology, cytology with partial genotyping, biomarkers p16/Ki-67, and DNA methylation. [27] [28] [29] However, the screening interval and optimal triage method will depend on perceived risk (among others), screening costs (both of the HPV assays and colposcopy), screening infrastructure and health-care budget. As this is likely to be setting specific, we carried out a 3-year prospective study, COMPACT, to compare the potential role of HPV16/18 partial genotyping and cytology in primary HPV cervical cancer screening in Japan and present the design, method and cross-sectional baseline results.
The present study has several limitations that need to be addressed. First, only screen-detected (verification bias-unadjusted) were not referred to colposcopy and, of those referred to colposcopy, biopsy was taken only in cases with abnormal findings.
However, there is considerable controversy regarding the merits of adjusting for verification bias. 12, 30 Not only is it unethical to send low-risk women for an invasive procedure that has the potential to be both mentally and physically traumatic, it has been shown that the proportion of women with a double-negative result (cytology negative, HPV negative) who willingly attend for colposcopy is low and these women are also likely to represent a biased sample. 13 A further limitation of the current study is that almost no women in this study were vaccinated against HPV; therefore, the results of this study will only apply to a non-vaccinated population. Finally, the high mean age of participants meant that the overall hrHPV prevalence was low. However, the rate of 
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